Douglas A Whittington

12PUBLICATIONS
107CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

|May 18, 2026
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.

|Apr 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers.

|Aug 29, 2025
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang

|May 06, 2025
CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors.

Katherine Lazarides, Justin L Engel, Michele Meseonznik

|Mar 04, 2025
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.

Kevin M Cottrell, Kimberly J Briggs, Alice Tsai

Pageof 2

Frequent Collaborators

9 joint publications

John P Maxwell

7 joint publications

Jannik N Andersen

6 joint publications

Alan Huang

6 joint publications

Yi Yu